Aardvark Therapeutics shared exploratory results from its early-terminated Phase 3 HERO trial and open-label extension for ARD-101, a drug targeting hyperphagia in Prader-Willi Syndrome (PWS). The data showed modest improvements in hunger scores during treatment, with ARD-101 generally well tolerated. The FDA has lifted the clinical hold on ARD-101, and Aardvark plans to meet with the FDA to discuss a new Phase 3 trial design, aiming to resume clinical activities in 2027 and advance toward potential approval.
Aardvark Therapeutics' recent clinical trial developments provide context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Oct 23, 2026 17:41 WIB: out of 150 priced health-sector US stocks tradable on Pluang, 42 rose and 97 fell. Notable movers include Moderna, Inc. (MRNA) at USD 194.71 with a 1-day change of -3.91% and Pluang order activity showing 71% Sell / 29% Buy, Nuvation Bio Inc. Class A (NUVB) at USD 4.85 with +3.19%, and Heron Therapeutics Inc (HRTX) at USD 0.30 with +2.97% and a buy order activity of 65%. Typical hold times on Pluang range from 7 to 58 days among these stocks.
Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...
Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...
eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...
